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Olmesartan, But Not Amlodipine,
Improves Endothelium-Dependent
Coronary Dilation in Hypertensive Patients
Masanao Naya, MD,* Takahiro Tsukamoto, MD,*§ Koichi Morita, MD,† Chietsugu Katoh, MD,‡
Tomoo Furumoto, MD,* Satoshi Fujii, MD,* Nagara Tamaki, MD,† Hiroyuki Tsutsui, MD*
Sapporo and Date, Japan
Objectives We aimed to compare the effects of the angiotensin II receptor blocker (ARB) olmesartan versus the calcium
channel blocker (CCB) amlodipine on coronary endothelial dysfunction in patients with hypertension.
Background Angiotensin II receptor blockers are thought to have greater beneficial effects than CCBs on coronary vasomo-
tion by directly blocking action of angiotensin II.
Methods Twenty-six patients with untreated essential hypertension were prospectively assigned to treatment with either
olmesartan (27.7  12.4 mg/day, n  13) or amlodipine (5.6  1.5 mg/day, n  13) for 12 weeks. Changes of
corrected myocardial blood flow (MBF) and coronary vascular resistance (CVR) from rest to cold pressor were
measured by using 15O-water and positron emission tomography before and after treatment. Blood biomarkers
including lipids, glucose, insulin, high-sensitivity C-reactive protein, interleukin-6, tumor necrosis factor-alpha,
and superoxide dismutase (SOD) were also measured.
Results Olmesartan and amlodipine reduced blood pressure (BP) to the same extent (28.7  16.2 mm Hg vs.
26.7  10.8 mm Hg). In the olmesartan group, MBF tended to be greater (0.15  0.19 ml/g/min vs.
0.03  0.17 ml/g/min, p  0.09 by 2-way analysis of variance), and CVR was significantly decreased (7.9 
23.5 mm Hg/[ml/g/min] vs. 16.6  18.0 mm Hg/[ml/g/min], p  0.05) after treatment, whereas these par-
ameters did not change in the amlodipine group (MBF: 0.15  0.12 ml/g/min vs. 0.12  0.20 ml/g/min;
CVR: 6.5  18.2 mm Hg/[ml/g/min] vs. 4.8  23.4 mm Hg/[ml/g/min]). Serum SOD activity tended to in-
crease (4.74  4.77 U/ml vs. 5.57  4.74 U/ml, p  0.07 by 2-way analysis of variance) only in the olmesartan
group.
Conclusions Olmesartan, but not amlodipine, improved endothelium-dependent coronary dilation in hypertensive patients
independent of BP reduction. These beneficial effects on coronary vasomotion might be via an antioxidant pro-
perty of ARBs. (J Am Coll Cardiol 2007;50:1144–9) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.06.013d
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Aypertension is a major risk factor of coronary artery disease
1). In hypertensive patients, coronary vasodilator response
s impaired (2), which is caused not only by the elevation of
lood pressure (BP) but also by inflammation and oxidative
tress in the vascular wall induced by angiotensin II (3,4).
Angiotensin II receptor blockers (ARB) and calcium
hannel blockers (CCB) are highly used in the treatment of
ypertension. Angiotensin receptor blockers have been
rom the Departments of *Cardiovascular Medicine, †Nuclear Medicine, and
Health Science, Hokkaido University Graduate School of Medicine, Sapporo, Japan;
nd the §Department of Cardiovascular Medicine, Date Red Cross Hospital, Date,
apan. This research was supported by grants-in-aid from the Ministry of Education,
ulture, Sports, Science, and Technology, Japan, and from Daiichi Sankyo Co. Ltd.,
nd by the Research Grant for Cardiovascular Diseases (16C-8) from the Ministry of
ealth, Labour, and Welfare, Japan.t
Manuscript received April 10, 2007; revised manuscript received May 24, 2007,
ccepted June 11, 2007.emonstrated to reduce inflammation (5) and oxidative
tress (4) via directly blocking the action of angiotensin II.
herefore, the effects of antihypertensive drugs on endothe-
ial function may differ between ARB and CCB.
Myocardial blood flow (MBF) could be measured by
sing oxygen-15–labeled (15O)-water positron emission to-
ography (PET). Myocardial blood flow and coronary
ascular resistance (CVR) response to cold pressor test
CPT) are feasible and repeatable variables for the nonin-
asive evaluation of coronary endothelium-dependent func-
ion (6,7). The severity of coronary endothelial dysfunction
as been demonstrated to be associated with the risk of
eveloping cardiovascular events and poor prognosis (8).
hus, this study was performed to compare the effects of
RB and CCB on endothelium-dependent coronary dila-ion in patients with essential hypertension. Furthermore,
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helial function was also evaluated.
aterials and Methods
atients. Twenty-six consecutive untreated and uncompli-
ated patients with essential hypertension (12 men and 14
omen; age 53.7  11.0 [ SD] years) were studied from
ecember 2004 to March 2006. They had systolic BP over
40 mm Hg and/or diastolic BP over 90 mm Hg by mercury
phygmomanometer, measured twice with an interval of 1
onth. Patients with a history or clinical evidence of recent
nfection, malignancies, coronary artery disease, peripheral
ascular disease, cerebrovascular disease, secondary hyper-
ension, diabetes mellitus with hemoglobin A1c 5.8%,
yperlipidemia with total cholesterol 260 mg/dl, wall
otion abnormalities by echocardiography, or receiving
edications were excluded. The patients were prospectively
ssigned to antihypertensive treatment with either olmesar-
an (27.7  12.4 mg/day, n  13) or amlodipine (5.6  1.5
g/day, n  13) for 12 weeks.
Informed consent was obtained from each study patient.
he study was approved by the institutional ethical com-
ittee, and the procedures were in accordance with insti-
utional guidelines.
reatment protocol. Blood pressure was measured before
nd 4, 8, and 12 weeks after treatment. At least 2 measure-
ents were made and the mean values of these measure-
ents were used. Patients had either 20-mg olmesartan or
-mg amlodipine daily. If systolic BP was 140 mm Hg or
iastolic BP was 90 mm Hg after 1 month, the dose was
oubled to 40-mg olmesartan or 10-mg amlodipine. If
ystolic BP was 110 mm Hg after 1 month, the dose was
alved to 10-mg olmesartan or 2.5-mg amlodipine. No
dverse effects of antihypertensive drugs were experienced.
lood chemical analysis. Blood samples were obtained
t the time of PET scans. Serum total cholesterol,
igh-density lipoprotein cholesterol, low-density li-
oprotein cholesterol, triglycerides, blood sugar, insulin,
igh-sensitivity C-reactive protein (hs-CRP), superoxide
ismutase (SOD) activity, plasma interleukin (IL)-6,
nd tumor necrosis factor (TNF)-alpha were measured.
omeostasis model assessment for insulin resistance
haracteristics of the Study Patients at Baseline
Table 1 Characteristics of the Study Patients at Baseline
Olmesartan
(n  13)
Amlodipine
(n  13) p Value
Age (yrs) 53.5 12.1 53.9 9.1 0.92
Gender (M/F) 7/6 5/8 0.43
BMI (kg/m2) 25.7 4.1 24.5 4.6 0.50
Smoking, n (%) 2 (15) 2 (15) 0.99
Duration of HT (yrs) 3.5 3.6 3.4 3.4 0.98
LVMI (g/m2) 101.4 19.5 99.7 18.9 0.82ata are expressed as mean  SD.
BMI  body mass index; HT  hypertension; LVMI  left ventricular mass index. pHOMA-IR) was calculated:
OMA-IR fasting blood sugar
insulin/405.
chocardiography. Left ven-
ricular mass index was measured
sing the M-mode guided echo-
ardiogram according to the
ethod recommended by the
merican Society of Echo-
ardiography.
ET scans. Myocardial blood
ow at rest and during CPT were
etermined using 15O-water and
ET before and after treatments.
ll patients abstained from
affeine-containing beverages for
t least 24 h and from smoking
or at least 12 h before the PET
tudy. All PET scans were per-
ormed with ECAT EXACT
R (Siemens/CTI, Knoxville,
ennessee) by modified methods
s previously reported (9). Cold
ressor test was performed as
ollows. The patient’s right foot
as immersed in ice water up to
he ankle. Sixty seconds later,
ET scanning of 15O-water was started, and the CPT was
ontinued for 4 min.
Reconstruction of emission sinograms and quantification
f MBF using a semiautomatic program were performed
ccording to methods previously reported (10).
Myocardial blood flow was corrected against rate pressure
roduct (RPP) to account for individual differences in
ardiac work as follows (9); MBF was divided by RPP and
ultiplied by 7,500, which is the average RPP at rest of
ealthy controls with age of 50.1  9.7 years.
P and HR at Rest Before and After Treatment
Table 2 BP and HR at Rest Before and After Treatment
Olmesartan (n  13)
Before
4 Weeks
After
8 Weeks
After
12 Weeks
After
SBP (mm Hg) 154 14 140 14 134 15 125 10
DBP (mm Hg) 100 14 88 12 84 11 82 11
HR (beats/min) 65 7 — — 65 7
Amlodipine (n  13)
Before
4 Weeks
After
8 Weeks
After
12 Weeks
After
SBP (mm Hg) 152 15 134 14 128 12 125 10
DBP (mm Hg) 101 8 88 7 85 7 85 8
HR (beats/min) 64 9 — — 64 8
ata are expressed as mean  SD.
Abbreviations
and Acronyms
ARB  angiotensin II
receptor blocker
BP  blood pressure
CCB  calcium channel
blocker
CPT  cold pressor test
CVR  coronary vascular
resistance
HOMA-IR  homeostasis
model assessment for
insulin resistance
IL  interleukin
MBF  myocardial blood
flow
15O-water  oxygen-15–
labeled water
PET  positron emission
tomography
RPP  rate pressure
product
SOD  superoxide
dismutase
TNF  tumor necrosis
factorBP  blood pressure; DBP  diastolic blood pressure;
ressure; —  not measured.HR  heart rate; SBP  systolic blood
w
r
c
e
(
u
T
C
S
S
b
o
c
w

f
r
t
b
p
c
R
S
a
a
b
t
(
0
M
C
g
2
m
2
c
C
n
i
r
t
g
i
b
C
c
m
t
(
n
g

t
A
s
a
B
t
l
s
1146 Naya et al. JACC Vol. 50, No. 12, 2007
Effects of ARB Versus CCB on Coronary Vasomotion September 18, 2007:1144–9The MBF, an index of coronary endothelial function,
as calculated as corrected MBF during CPT minus cor-
ected MBF at rest (11). Coronary vascular resistance was
alculated by dividing mean BP by MBF to exclude the
ffects of coronary perfusion pressure as previously reported
11). Coronary vascular resistance during CPT was also
sed as an index of coronary endothelial function (8,11).
he CVR was calculated as CVR during CPT minus
VR at rest.
tatistical analyses. All data were expressed as mean 
D. Baseline characteristics between groups were compared
y an unpaired t test. Within treatment groups, the changes
f corrected MBF and CVR from rest to CPT were
ompared by a paired t test. Between-group comparisons
ith regard to hemodynamic, blood biomarkers, RPP,
MBF, and CVR before and after treatment were per-
ormed by 2-way analysis of variance (ANOVA) with
epeated measures, followed by Scheffé’s test if the interac-
ion was significant. Univariate analysis of the association
etween serum SOD activity and CVR during CPT was
erformed with the use of linear regression. A p  0.05 was
onsidered to be statistically significant.
esults
tudy patients. Table 1 shows the baseline clinical char-
cteristic data for the study patients. Both olmesartan and
mlodipine reduced BP 12 weeks after treatment (p  0.51
y 2-way ANOVA with repeated measures) (Table 2), and
he extent of BP reduction was the same between groups
28.7  16.2 mm Hg vs. 26.7  10.8 mm Hg, p 
Figure 1 Corrected MBF in Response to CPT Before and After
Corrected myocardial blood flow (MBF) in response to cold pressor test (CPT) befo
(n  13; left panel) and amlodipine (n  13; right panel). The central bar on the.71). CBF response to CPT. The increase in RPP from rest to
PT was comparable before and after treatment between
roups (olmesartan: 2,410  1,823 mm Hg/min vs.
,523  1,528 mm Hg/min; amlodipine: 2,925  1,298
m Hg/min vs. 2,639  1,504 mm Hg/min, p  0.49 by
-way ANOVA with repeated measures). Before treatment,
orrected MBF was significantly decreased from rest to
PT in both groups. After treatment, corrected MBF did
ot change from rest to CPT in olmesartan group, whereas
t tended to decrease in amlodipine group (Fig. 1). Cor-
ected MBF during CPT was significantly increased after
reatment in the olmesartan group but not in the amlodipine
roup (Fig. 1). The increase of MBF tended to be greater
n the olmesartan group than in amlodipine group (p 0.09
y 2-way ANOVA with repeated measures) (Fig. 2).
VR response to CPT. Before treatment, CVR did not
hange from rest to CPT in either group. After treat-
ent, CVR significantly decreased from rest to CPT in
he olmesartan group, but not in the amlodipine group
Fig. 3). Coronary vascular resistance during CPT sig-
ificantly decreased after treatment in the olmesartan
roup, but not in the amlodipine group. The decrease of
CVR was significantly greater in the olmesartan group
han in the amlodipine group (p  0.05 by 2-way
NOVA with repeated measures) (Fig. 4). The CVR
ignificantly decreased after olmesartan but not after
mlodipine (Fig. 4).
lood biochemical markers. Blood biomarkers including
otal cholesterol, high-density lipoprotein cholesterol,
ow-density lipoprotein cholesterol, triglycerides, blood
ugar, insulin, HOMA-IR, TNF-alpha, IL-6, and hs-
ment
after treatment with olmesartan
al bars represents the mean  SD.Treat
re and
verticRP were comparable between groups (Table 3). Serum
S
p
A
c
S
g
a
D
T
h
i
c
i
s
n
S
t
t
c
e
1147JACC Vol. 50, No. 12, 2007 Naya et al.
September 18, 2007:1144–9 Effects of ARB Versus CCB on Coronary VasomotionOD tended to increase in the olmesartan group com-
ared with the amlodipine group (p  0.07 by 2-way
NOVA with repeated measures). There was a signifi-
ant negative correlation between the changes in serum
OD activity and CVR during CPT in the olmesartan
roup, whereas no such correlation was observed in the
mlodipine group (Fig. 5).
iscussion
he present study demonstrated that 12-week treatment of
ypertensive patients with olmesartan, but not amlodipine,
Figure 2 MBF in Response to CPT
Before and After Treatment
The MBF from rest to CPT before and after treatment with olmesartan
(n  13) and amlodipine (n  13). Abbreviations as in Figure 1.
Figure 3 CVR in Response to CPT Before and After Treatment
The coronary vascular resistance (CVR) in response to cold pressor test (CPT) befo
with olmesartan (n  13; left panel) and amlodipine (n  13; right panel). The cemproved endothelium-dependent coronary dilation despite
omparable BP reduction. Serum SOD activity tended to
ncrease only in the olmesartan group. Notably, there was a
ignificant relationship between the improvement of coro-
ary endothelial dysfunction and the increase in serum
OD by olmesartan.
Previous studies (12) demonstrated that CCB improves
he vasodilation of the epicardial coronary arteries in hyper-
ensive patients. However, in the case of nonobstructed
oronary arteries, MBF is not regulated by the conduit
picardial coronary arteries, but rather by the coronary
d after treatment
ar on the vertical bars represents the mean  SD.
Figure 4 CVR in Response to CPT
Before and After Treatment
The CVR from rest to CPT before and after treatment with olmesartan
(n  13) and amlodipine (n  13). Abbreviations as in Figure 3.re an
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oronary tree. Therefore, the present study suggested that
RB, but not CCB, might improve the endothelial
unction in coronary microcirculation, which is most
rone to be affected by damaging cardiovascular risk
actors such as hypertension (2). Consequently, any
reatment strategy mostly targeting coronary microcircu-
ation would be expected to prevent early episodes of
yocardial ischemia by keeping coronary resistance as
ow as possible during high flow demand situations. The
resent study has thus provided direct evidence to suggest
hat ARB has such beneficial effects on coronary micro-
irculation.
Some groups previously reported the similar effects of
ngiotensin-converting enzyme inhibitors on MBF in re-
ponse to dipyridamole (13). However, they compared the
ffects of angiotensin-converting enzyme inhibitors to those
y placebo, which did not allow us to comment on any
ffects beyond BP lowering. In addition, a previous study
14) found a beneficial effect of an ACE inhibitor (lisino-
Blood Biochemistry Before and After Treatment
Table 3 Blood Biochemistry Before and Afte
Olmesartan (n
Before
Total cholesterol (mg/dl) 209.1 32.8
HDL cholesterol (mg/dl) 66.5 21.8
LDL cholesterol (mg/dl) 123.5 30.5
Triglycerides (mg/dl) 116.6 55.9
Blood sugar (mg/dl) 101.4 8.5
Insulin (mU/l) 6.47 2.93
HOMA-IR 1.61 0.71
IL-6 (pg/ml) 2.65 4.02
TNF-alpha (pg/ml) 1.11 0.29
hs-CRP (ng/ml) 998 1.433
SOD activity (U/ml) 4.74 4.77
Data are expressed as mean  SD.
HDL high-density lipoprotein; HOMA-IR hemeostasis model asse
 interleukin; LDL  low-density lipoprotein; SOD  superoxide dism
Figure 5 Relationship Between the Changes of CVR During CP
Relationship between the changes in CVR during CPT and serum superoxide dismu
activity after treatment with olmesartan (n  13)  (A) and amlodipine (n  13) (B)ril) but not ARBs (losartan) on MBF response to dipyrid-
mole. However, first, not all ARBs have the same effects on
oronary microcirculation (i.e., olmesartan seems to have
uch an effect, but not losartan). Second, the present study
sed the CPT, which is an established stimulus mostly
ependent on endothelial function (6,7,11), whereas the
revious study used dipyridamole, which is less
ndothelium-dependent.
The present study demonstrated that the augmentation of
erum SOD by olmesartan might be involved in the
mprovement of coronary endothelial function. In addition,
RB can directly inhibit angiotensin II-mediated superox-
de production (15). These results suggest that the antiox-
dant effects of olmesartan are specific for this ARB and
iffer from unspecific effects of vitamin C. More impor-
antly, these effects of olmesartan can explain the contrast-
ng results, in which ARB losartan failed to improve MBF
esponse to dipyridamole (14), whereas olmesartan could
xert beneficial effects on coronary microcirculation, as seen
n the present study.
atment
Amlodipine (n  13)
fter Before After
 33.7 194.1 33.1 209.6 47.8
 23.3 59.0 10.1 65.2 17.0
 25.9 119.7 31.7 127.9 47.9
 105.2 124.8 104.9 120.2 96.4
 7.5 98.9 7.7 97.2 9.4
 5.94 6.98 5.36 5.3 3.10
 1.48 1.74 1.36 1.32 0.87
 2.68 1.63 1.64 1.35 1.17
 0.34 1.12 0.37 1.17 0.38
 1,055 760 935 815 896
 4.74 3.09 3.09 3.09 1.26
t for insulin resistance; hs-CRP high-sensitivity C-reactive protein; IL
NF  tumor necrosis factor.
Serum SOD Activity After Treatment
SOD)
viations as in Figure 3.r Tre
 13)
A
204.4
67.6
118.2
133.5
99.7
8.3
2.07
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September 18, 2007:1144–9 Effects of ARB Versus CCB on Coronary Vasomotiontudy limitations. First, the present study was not a
linded, randomized study. However, the characteristics of
he study patients were well matched between the 2 groups
Tables 1 to 3). Importantly, MBF, CVR, and blood
iomarkers were measured and analyzed by another group
f investigators who were blinded to the treatment groups.
econd, central BP measurement, as in the CAFE (Conduit
rtery Function Evaluation) study (16), which might affect
BF more effectively than peripheral BP, was not available
n the present study. Therefore, a further study is clearly
eeded to evaluate the relation between the central BP and
BF.
onclusions
he ARB olmesartan, but not the CCB amlodipine, im-
roved endothelium-dependent coronary dilation assessed
y 15O-water PET in hypertensive patients independent of
P lowering. These beneficial effects might contribute to
he cardioprotective benefits of ARB in the treatment of
ypertension, which warrants further investigation.
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